Clinical Trial Update: Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating an every-3-week dosing regimen of ixabepilone in metastatic breast cancer patients previously treated with anthracyclines and resista…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ixempra (ixabepilone)

Snippet

Sponsor: R-Pharm | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED